Aera Technology Releases New Capabilities to Accelerate Decision Intelligence Adoption
6.6.2022 20:00:00 EEST | Business Wire | Press release
Gartner Supply Chain Symposium/Xpo™ 2022 — Aera Technology today announced from the Gartner® Supply Chain Symposium/Xpo™ 2022, the release of new AI/MLOps and developer capabilities for its Aera Decision Cloud™ platform. To speed and scale decision automation, these enhancements add to the platform’s data science engine and provide advanced features for understanding the relationships and effectiveness of decisions. The innovations also strengthen Aera Decision Cloud’s capabilities for supply chain decision flows.
Aera Decision Cloud is designed to accelerate the adoption of Decision Intelligence — the digitization, augmentation, and automation of decision making. It enables companies to make and execute decisions in real-time to optimize business, financial, and operational performance.
According to Gartner, “by 2025, 95% of decisions that currently use data will be at least partially automated.”* Implementing and scaling automated decision-making across one or multiple business functions is difficult and time-consuming without a purpose-built platform. Aera Decision Cloud was designed from the start to empower users with the advanced technologies and tools, in one platform, to aggregate and integrate data from internal and external systems and sources and build and deploy decision-making models that generate informed, automated recommendations for any business scenario.
Today’s product release provides new features for business users that advance and scale Aera Cognitive Skills™ — the platform’s pre-built set of comprehensive decision-making capabilities for demand forecasting, planning, inventory, logistics, procurement, finance, revenue, and more. The release also delivers enhancements for data engineers, data scientists, and developers that optimize their experience in Aera Developer™, the platform’s integrated development environment (IDE) for creating and deploying Skills, or modifying any deployed Aera Cognitive Skills.
Product release highlights:
-
Enhancements to Aera Cortex™, the data science engine inside the Aera Cognitive Operating System™, to improve the user experience, including:
- New Aera Notebook: Jupyter Notebook open interface provides the ideal environment to easily integrate data science projects and other custom code using Python and R, into Decision Intelligence flows, right from the Aera Decision Cloud platform.
- New AutoML: Machine learning options enable development of ML decision models — without requiring expertise in model creation, tuning, and deployment.
- New Model Performance and Versioning: New enhancements automate monitoring, deployment, and versioning of machine learning models to make it much easier to operationalize ML models and scale across the entire enterprise.
-
Advanced intelligence capabilities to provide a deeper understanding of relationships and effectiveness of decisions, including:
- New Graph Explorer: Advanced graph capabilities to enable data relationships to be used effectively in the decision-making process.
- New Confidence Score: Confidence score framework, which learns from past, similar recommendations and outcomes, helps determine the decisions that can be automated.
- New Action Item Node: Addition of a node within the Aera Developer environment to simplify decision management through the ability to more easily create, update, close, and access recommendations.
“Through Aera Decision Cloud, we are re-inventing decision making and accelerating adoption of Decision Intelligence,” said Shariq Mansoor, Founder and Chief Technology Officer, Aera Technology. "Today’s comprehensive release for both business end user and data science teams underscores how we are continually advancing and evolving our platform to enable digital decisions at scale in this increasingly complex business environment.”
To see a demo of Aera Decision Cloud and the new features, visit the Aera team at Booth #325, Gartner Supply Chain Symposium/Xpo™ 2022.
About the Gartner Supply Chain Symposium/Xpo™
Gartner Supply Chain Symposium/Xpo delivers the must-have insights, strategies and frameworks for CSCOs and supply chain leaders to drive impact within their organizations. Supply chain leaders will gather to gain a strategic view of the trends disrupting their business and the insights and frameworks they can use to prepare for disruption, enable digital transformation and build sustainability as a competitive advantage.
*Gartner, “ Predicts 2022: Data and Analytics Strategies Build Trust and Accelerate Decision Making,” Jorgen Heizenberg, Lydia Clougherty Jones, Ted Friedman, Andrew White, Saul Judah, Gareth Herschel, Rita Sallam, Ehtisham Zaidi, Svetlana Sicular, December 2021. https://www.gartner.com/document/4008991
GARTNER and SUPPLY CHAIN SYMPOSIUM/XPO ™ are registered trademarks and service marks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.
About Aera Technology
Aera Technology is the Decision Intelligence company that makes business agility happen. The company’s innovative cloud platform integrates with existing systems to make and execute business decisions in real time. In the era of digital acceleration, Aera helps enterprises around the world transform how they respond to the ever-changing environment. For more information, visit www.aeratechnology.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005098/en/
Contact information
Zoe Kine
Zoe.kine@aeratechnology.com
Ph: 415-497-5285
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom